Intellia Therapeutics - NTLA Stock Forecast, Price & News

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Analyst Ratings Changes

A number of equities research analysts have weighed in on NTLA shares. SVB Leerink cut their target price on Intellia Therapeutics from $155.00 to $152.00 and set an "outperform" rating for the company in a research report on Friday, August 5th. StockNews.com upgraded Intellia Therapeutics to a "sell" rating in a research report on Friday, August 5th. Oppenheimer dropped their price target on Intellia Therapeutics from $160.00 to $130.00 in a report on Monday, May 9th. Credit Suisse Group upped their price target on Intellia Therapeutics to $101.00 in a report on Tuesday, August 9th. Finally, Bank of America began coverage on Intellia Therapeutics in a report on Thursday, June 16th. They issued a "buy" rating and a $70.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, Intellia Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $128.00.

Intellia Therapeutics Trading Up 1.0 %

NASDAQ:NTLA traded up $0.68 during trading hours on Monday, hitting $68.42. 831,841 shares of the stock traded hands, compared to its average volume of 1,216,280. The firm has a 50 day moving average price of $57.81 and a 200 day moving average price of $63.14. Intellia Therapeutics has a fifty-two week low of $37.08 and a fifty-two week high of $180.59. The firm has a market cap of $5.20 billion, a price-to-earnings ratio of -12.79 and a beta of 2.00.

Intellia Therapeutics (NASDAQ:NTLA - Get Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($1.33) earnings per share for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.03). Intellia Therapeutics had a negative return on equity of 40.23% and a negative net margin of 883.17%. The company had revenue of $14.00 million during the quarter, compared to analyst estimates of $9.50 million. During the same period last year, the company posted ($1.01) earnings per share. The company's revenue was up 115.4% compared to the same quarter last year. Research analysts predict that Intellia Therapeutics will post -5.83 EPS for the current year.